HEALTH● LOWAug 14 · Aug 14, 2026, 5:28 AM
Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026
Seeking Alpha Tech
Kyntra Bio aims for a median rPFS of 10 months or more for FG-3246 and plans to begin a Phase III trial for roxadustat in Q4 2026. This indicates developments in the company's drug pipeline and clinical trial schedule.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoWhy Did Pawn Star Rick Harrison Need Emergency Bypass Surgery ? mix1043fm.com · United StatesHEALTH2h agoAgostina Hein withdrew from the South American Games due to her recovery after an appendicitis operationClarínHEALTH2h agoCourt records indicate insanity defense for woman charged in Hoffman deathkctv5.com · United StatesHEALTH2h agoT - Boz Steps Back From Tour to Focus on Her Healththeroot.com · United States